Results 11 to 20 of about 1,206 (142)
IGF-1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response. [PDF]
Adv Sci (Weinh)IGF‐1 deficiency underlies poor ovarian response (POR), as reduced levels in follicular fluid and granulosa cells impair antral follicle formation and compromise reproductive outcomes. Including IGF‐1 as a biomarker significantly enhances the accuracy of models predicting both PORrisk and pregnancy success.
Hu Z +9 more
europepmc +2 more sources
Optimized Signal Peptide for Secretory Expression of Human Recombinant Somatropin in E. coli [PDF]
Advanced Pharmaceutical Bulletin, 2023 Purpose: The human somatropin is a single-chain polypeptide with a pivotal role in various biological processes. Although Escherichia coli is considered as a preferred host for the production of human somatropin, the high expression of this protein in E.
Zeynab Ahmadi +7 more
doaj +1 more source
Frontiers in Endocrinology, 2022 BackgroundChildren with growth hormone deficiency (GHD) are treated with daily somatropin injections; however, poor treatment persistence and adherence have been recognized previously and have been shown to negatively impact growth outcomes.
Jane Loftus +10 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2023 Background Somatropin treatment is indicated in a variety of disorders including growth hormone (GH) deficiency, Prader–Willi and Turner syndrome, chronic renal insufficiency and others. To date, almost all studies have been limited to single GH products,
Dirk Schnabel +6 more
doaj +1 more source
Somatropin therapy in italian adults with growth hormone deficiency
BMC Endocrine Disorders, 2022 Background In adult population, Growth Hormone Deficiency (GHD) is a complex clinical condition with heterogeneity of causes and duration. Growth Hormone (GH) replacement therapy has beneficial effects entailing a chronic and expensive use.
Flavia Pricci +5 more
doaj +1 more source
Frontiers in Endocrinology, 2023 IntroductionThe standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing.
Roy Gomez +8 more
doaj +1 more source
Association of Growth Hormone Adherence and Growth Outcomes in Paediatric Patients: Results From a Clinical Registry. [PDF]
Clin Endocrinol (Oxf)ABSTRACT Objective Daily growth hormone (GH) therapy for growth disorders requires long‐term adherence. The aim of this study was to investigate the association of adherence with 2‐year growth outcomes in paediatric patients receiving daily GH therapy in a clinical registry. Design Retrospective cohort study. Patients Patients with growth disorder were
Rohrer TR +5 more
europepmc +2 more sources
Epidemiology of acquired hypothalamic obesity following traumatic brain injury and nonspecific hypothalamic microinjury: A nationwide German claims data analysis. [PDF]
J NeuroendocrinolAbstract Acquired hypothalamic obesity (aHO) is characterized by rapid and persistent weight gain resulting from structural or functional damage to the hypothalamus, typically accompanied by neuroendocrine dysfunction. While aHO is well described in the context of hypothalamic or suprasellar tumors, particularly craniopharyngioma, little is known about
Witte J +5 more
europepmc +2 more sources
Frontiers in Endocrinology, 2022 BackgroundTo evaluate the safety and efficacy of daily somatropin (Jintropin®), a recombinant human growth hormone, in prepubertal children with ISS in China.MethodsThis study was a multicenter, randomized, controlled, open-label, phase 3 study.
Jinna Yuan +11 more
doaj +1 more source